3rd January 2019
("Physiomics") or ("the Company")
Physiomics signs collaboration agreement with UK Medicines Discovery Catapult
Physiomics plc (AIM: PYC), is pleased to announce that it has entered into a strategic collaboration with the Medicines Discovery Catapult ("MDC"). Physiomics will be part of the MDC's "Virtual R&D" network of advisors and available to provide advice to the many small biotechnology companies supported by the MDC from its Alderley Park base. Under the terms of the agreement the MDC will introduce Physiomics to selected potential clients and in return will receive a small commission on the value of any service contracts arising from such introductions.
Physiomics offers a range of services including its proprietary Virtual Tumour technology to predict the effect of oncology drugs and improve the success rate of oncology R&D. It works with companies ranging from start-ups to some of the world's largest pharmaceutical companies and has experience in a wide range of treatments, including radiation, DNA repair inhibitors and immune therapies.
The MDC was established by Innovate UK (part of UK Research & Innovation) to support the discovery and evaluation of medicines by providing access to expert technical capabilities, equipment and other resources required to take new ideas from concept to reality. Its Virtual R&D group supports UK-based biotech companies by conducting diligence on their programs as well as through project management and by connecting them to a variety of expert consultants and service providers.
Dr Jim Millen, CEO said: "We are delighted to be working with the MDC; an organisation that plays such a key role in supporting emerging biotech companies in the UK. We're also excited by the potential that this new relationship offers to connect Physiomics to emerging players in the field of oncology."
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.
For more information please visit:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.